Opinion: It’s not the mission of universities to perpetuate inequity. Why do Emory and others do that?
As billions of people in the Global South continue to confront Covid-19 unprotected because they cannot access vaccines, a recent announcement regarding a new, potentially effective therapy offered a glimmer of hope.
In late-stage clinical trials, a new antiviral pill from Merck, called molnupiravir, cut hospitalizations and deaths from Covid-19 by one-third. A federal advisory committee, in a narrow vote, recommended that the Food and Drug Administration authorize emergency use of the drug as the first oral treatment for Covid-19. If authorized, it could potentially become available for patients in the United States within weeks.
